BioNTech SE, located in Mainz, Germany, is a biotechnology company that creates active immunotherapies for the individualized treatment of disease. It's also considered as one of the the largest biotech companies in Germany. It develops mRNA-based pharmaceutical candidates such as engineered cell therapy, novel antibodies, and small molecule immunomodulators for the treatment of cancer, as well as vaccines against infectious diseases and protein replacement therapies for rare diseases.

To develop treatments for cancer and beyond, the business has coupled ground-breaking research with cutting-edge technologies to pioneer the next generation of patient-specific immunotherapies. Different modes of action, high precision targeting, potency, and efficacy have been optimized across its wide range of platform products, which include mRNA therapeutics, engineered cell therapies, antibodies, and small molecule immunomodulators. BioNTech is also creating its own cutting-edge manufacturing procedures to supplement the drug development platforms.

BioNTech is dedicated to improving people's health around the world via fundamental research and development of immunotherapies that harness the full power of the immune system to treat cancer, infectious illnesses, and other serious diseases. BioNTech collaborates together with some of the world's most prestigious pharmaceutical corporations and non-profit organizations to advance medical knowledge, therapeutic innovation, and quality of care. As driving forces, the company believes in scientific rigor, innovation, and passion. Scientists and clinicians founded BioNTech to translate knowledge into survival by combining foundational research with operational expertise.

Founded: 2008
Headquarters: Mainz, Germany
Website: https://www.biontech.com/

Evotec SE is a publicly traded medication discovery and development firm based in Hamburg, Germany. The company operates on a global scale, primarily through partnerships with pharmaceutical and biotechnology companies, academic institutions, patient advocacy groups, and venture investors. Evotec has a market capitalization of €7.5 billion as of December 31, 2021, with a pipeline of more than 130 partnered programs in discovery, pre-clinical development, and clinical development.

The objective of Evotec is to find and develop highly effective treatments and make them available to patients worldwide. To that end, Evotec has established itself as a global platform company, leveraging its data-driven multimodality platform for both proprietary and collaborative research, and employing a one-of-a-kind combination of innovative technologies for the discovery and development of first-in-class and best-in-class pharmaceutical products. Its partner network includes all Top 20 Pharma firms as well as hundreds of biotechnology businesses, academic institutions, and other healthcare players. Evotec has strategic initiatives in a wide range of therapeutic areas that are currently underserved, such as neurology, cancer, metabolic and infectious illnesses.

Evotec's goal in these areas of expertise is to build a world-class co-owned pipeline of new treatments and make them available to patients worldwide. Through date, the Company has built a portfolio of over 200 proprietary and co-owned R&D projects ranging from early discovery through clinical development. Evotec employs over 4,500 highly qualified employees across 17 sites in six countries spanning Europe and the United States. The Company's locations in Hamburg (HQ), Cologne, Goettingen, Halle/Westphalia, and Munich (Germany), France, the United Kingdom, Italy, Australia, and the United States provide highly synergistic technologies and services and function as complementary clusters of excellence.

Founded: 1993
Headquarters: Hamburg, Germany
Website: https://www.evotec.com/

Amgen is a top biotechnology company in the globe as well as one of the the largest biotech companies in Germany. Amgen is a values-driven firm that uses research and innovation to turn fresh ideas and discoveries into medications for patients suffering from critical illnesses. Amgen is dedicated to unlocking the promise of biology for patients suffering from serious illnesses through the discovery, development, production, and delivery of novel human medicines. To unravel the complexity of disease and grasp the principles of human biology, this method begins with technologies such as advanced human genetics.

Amgen employs its expertise in areas with high unmet medical need to develop treatments that improve patients' health and quality of life. Since its founding in 1980, biotechnology pioneer Amgen has become a global leader among independent biotechnology companies, serving millions of patients around the world and developing a series of potentially game-changing drugs. It operates in close to a hundred different nations and territories, and its ground-breaking medicines have given hope to millions of individuals struggling with serious conditions like cancer, heart disease, osteoporosis, asthma, rheumatoid arthritis, and many more.

Millions of severely ill patients throughout the world rely on the consistent production of injectable or intravenous biological treatments. As a world-renowned leader in the production of biologics, Amgen has a history of providing life-saving treatments to those in need. Amgen's mission is to help people by turning the promise of science and biotechnology into medications that can improve or save patients' health.

Founded: 1989
Headquarters: Munich, Germany
Website: https://www.amgen.de/

In the fields of molecular diagnostics, applied testing, academic research, and pharmaceutical discovery, QIAGEN is unrivaled as a source of sample and assay technologies. In the fields of Molecular Diagnostics (human healthcare) and Life Sciences (academic, pharmaceutical R&D, and industrial applications, especially forensics), QIAGEN has over 500,000 customers across the world. There are almost 35 locations spread throughout 25 different nations. The QIAGEN group's international headquarters, QIAGEN N.V., is located in the Dutch city of Venlo. Regional headquarters serve Europe and the Americas from Hilden, Germany; North America from Germantown, Maryland; and Asia from Shanghai, China.

Sample to Insight solutions are what we at QIAGEN are all about; they are the tools and services we offer to help our customers gain valuable insights from any biological sample, be it for basic research or clinical healthcare. Customers from all over the world will benefit from the kits, which may be used for anything from a single, crucial step to an entire laboratory process. Its goal of making life better is an inspiring one that reflects its ambition.

QIAGEN's dedication to the markets, clients, and patients it serves is what propels it to the forefront of innovation and leadership across all industries that require Sample to Insight solutions. However, the company's success and reputation rest on the exceptional talent, skill, and enthusiasm of its employees. Both are contributing to the growth and success of the molecular biology revolution.

Founded: 1984
Headquarters: Hilden, Germany
Website: https://www.qiagen.com/

CureVac would be the next the largest biotech company in Germany. CureVac N.V. is a German biotech business that develops messenger RNA (mRNA) therapeutics. CureVac was regarded as a ray of hope for the development of a German vaccine at the start of the COVID-19 epidemic. The federal government put $300 million into the enterprise. First, the CureVac vaccine was delayed due to minor issues, while Pfizer-backed BioNTech created the highly effective BNT162b2. However, by mid-2021, it was clear that the CureVac-vaccine was only 47 percent effective and was still a long way from approval.

The company's primary goal is to create vaccinations for infectious diseases as well as medications to treat cancer and uncommon diseases. In addition to the German government, CureVac has partnerships with Boehringer Ingelheim, Sanofi Pasteur, Johnson & Johnson, Genmab, the Bill & Melinda Gates Foundation, Eli Lilly and Company, GlaxoSmithKline, the Coalition for Epidemic Preparedness Innovations, and the International AIDS Vaccine Initiative.

CureVac demonstrated the potential of mRNA to treat diseases and generate vaccines with a single discovery. CureVac, which was created in 2000, is the world's first startup to successfully harness mRNA for medical applications. It is at the forefront of developing a whole new class of medications based on messenger RNA (mRNA). The main idea is to employ this molecule as a data carrier for information, allowing the body to manufacture its own active chemicals to treat various ailments.

Founded: 2000
Headquarters: Tübingen, Germany
Website: https://www.curevac.com/

Rentschler Biopharma is a premier contract development and manufacturing organization (CDMO) specializing in client projects. Rentschler Biopharma provides process development and manufacture of biopharmaceuticals, as well as related consultancy operations such as project management and regulatory support, from its headquarters in Laupheim, Germany, and its plant in Milford, MA, USA. Rentschler Biopharma's high quality is demonstrated by its extensive expertise and excellence as a client solution partner.

A high-level quality management system, a well-established operational excellence culture, and cutting-edge technology ensure product quality and productivity at every stage of development and production. Rentschler Biopharma has formed a strategic agreement with Leukocare AG in order to provide best-in-class formulation development across the biopharmaceutical value chain. The company's structure ensures quick decision-making as well as effective and smooth-running procedures in order to meet project deadlines. Rentschler Biopharma established a reputation as a biotechnology pioneer through the early development of various interferon medicines.

Rentschler Biopharma contributes significantly to biopharmaceutical production, thereby satisfying the demands of developing therapeutics and assisting millions of patients on a daily basis. It is among the finest in the market and has established new benchmarks in client focus, specific personalized solutions, and dependability. It has quickly established itself as an international CDMO in its field. Its performance in the present and future is driven by its conviction.

Founded: 1927
Headquarters: Laupheim, Germany
Website: https://www.rentschler-biopharma.com/

Biogen Germany is one of the the largest biotech companies in Germany, and since its inception 26 years ago, it has been able to improve the lives of thousands of people suffering from serious illnesses such as multiple sclerosis or spinal muscular atrophy through research and innovative therapies. Biogen is still developing groundbreaking medications and solutions for patients all around the world. It undertakes research where others have reached their limits, giving sufferers with complex neurological and immunological disorders new hope.

Biogen is developing a pipeline of possible treatments in neurology, neuropsychiatry, specialized immunology, and rare illness, and the company is laser-focused on its mission of serving humanity through science and building a healthier, more sustainable, and equitable society. Biogen, as a pioneer, has been instrumental in driving medical development in neurology and biotechnology since its inception. Biogen is still developing groundbreaking medications and solutions that have the potential to enhance the lives of many individuals suffering from terrible illnesses.

Biogen has been at the forefront of numerous ground-breaking inventions, including a broad portfolio of medications to treat multiple sclerosis, the first licensed treatment for spinal muscular atrophy, and two co-developed therapeutics to target a distinguishing pathology of Alzheimer's disease. Biogen's mission is to enhance healthcare by pioneering research and worldwide development, manufacturing and commercial capabilities, and adhering to the commitment to and principles of sustainability.

Founded: 1997
Headquarters: München, Germany
Website: https://www.biogen.de/

Leica Biosystems (established in 1989) is a medical device firm that develops and sells clinical diagnostics to pathology labs. It is also a Danaher Corporation division and a research, instrument, and medical device company. It is the world's leading provider of workflow solutions, with the most comprehensive portfolio ranging from biopsy through diagnosis. From specimen preparation and staining through imaging and reporting, the company offers a comprehensive product line for every stage of the pathology process.

Leica Biosystems enables healthcare practitioners to provide correct diagnoses swiftly and consistently, translating concern into solutions for millions of patients worldwide. Its innovation is propelled by R&D investment, guided by customer feedback, and supported by a substantial patent portfolio. The organization is working hard to achieve the goal of enabling clinicians to rapidly offer patients with a very reliable diagnosis within 24-hours of biopsy.

Leica Biosystems is ideally positioned to break down the boundaries between each phase since it is the only business that owns the whole workflow from biopsy to diagnosis. The company's goal is to make diagnosis achievable within 24 hours after a biopsy. According to US News & World Report, 100 percent of the top 50 cancer facilities in the United States trust Leica Biosystems. Recent advances have concentrated on digital pathology with the introduction of the Aperio VERSA and LV1 scanners and histology equipment, including a next-generation H&E stainer.

Founded: 1989
Headquarters: Wetzlar, Germany
Website: https://www.leicabiosystems.com/

Next one in the list of the largest biotech companies in Germany, Toplist would like to mention Miltenyi Biotec. Miltenyi Biotec is a multinational biotechnology business headquartered in Bergisch Gladbach, Germany, near Cologne. The company offers goods and services to scientists, clinical researchers, and clinicians in the fields of basic research, translational research, and clinical applications. The company develops solutions for sample preparation, cell separation, cell sorting, flow cytometry, cell culture, molecular analysis, clinical applications, and small animal imaging techniques.

Miltenyi Biotec products have been acknowledged in over 20,000 papers and utilized in over 35,000 clinical trials. CiteAb, an antibody search engine that lists 4591 Miltenyi Biotec products, can be used to access many of the papers that have cited Miltenyi Biotec products. Instruments, reagents, and services from Miltenyi Biotec enable fundamental research, clinical research, and the conversion of basic research findings into practical applications that improve human health and treat severe disease.

Miltenyi Biotec's objective is to promote scientific understanding and medicine by delivering solutions for cell and gene therapy as well as biomedical research. It sees biomedical science as the most powerful force in changing how we treat cancer, autoimmune illnesses, and neurodegenerative disorders. Therapeutic design is shifting from chemistry-based science to individual treatments emphasizing cell-based techniques and more focused medications. It is driving the revolution that is redefining medicine and progressing it to the point where cancer and other serious diseases will be a thing of the past.

Founded: 1989
Headquarters: Bergisch Gladbach, Germany
Website: https://www.miltenyibiotec.com/DE-en/

Vertex is a multinational biotechnology business that invests in scientific research to develop breakthrough treatments for patients suffering from serious and life-threatening diseases. It identified and developed the first treatments for cystic fibrosis (CF), a rare, life-threatening hereditary condition. Vertex has more than a dozen current research studies focused on the underlying mechanisms of other critical diseases, in addition to clinical development programs in CF.

Science Magazine, The Boston Globe, The Boston Business Journal, and the San Diego Business Journal have all named Vertex as one of the best places to work in the industry. Its research and treatments have also won prestigious prizes such as the Robert J. Beall Therapeutics Development Award, the French Prix Galien, and the British Pharmacological Society.

The mission is to improve the quality of life for those living with critical diseases through the research, development, and distribution of novel therapeutics. Vertex's research pipeline is extensive and includes potential game-changing treatments for a wide range of diseases and conditions, such as cystic fibrosis, pain, sickle cell disease, beta thalassemia, alpha-1 antitrypsin deficiency, APOL1-mediated kidney disease, Duchenne muscular dystrophy, type 1 diabetes, and more. Vertex prioritizes specialist markets and invests in cutting-edge research to develop game-changing treatments for life-threatening illnesses.

Founded: 1989
Headquarters: München, Germany
Website: https://www.vrtx.de/